This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2021 Jun 25;6(1):241.

doi: 10.1038/s41392-021-00583-7.

GPR160 is a potential biomarker associated with prostate cancer

Wanjing Guo^#^{1

2}, Junyu Zhang^#³, Yan Zhou¹, Caihong Zhou¹, Yunjie Yang³, Zhaotong Cong⁴, Jibin Dong⁴, Dehua Yang^{5

6}, Bo Dai⁷, Ming-Wei Wang^{8

9

10}

Affiliations

Affiliations

¹ The National Center for Drug Screening and CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CAS), Shanghai, China.
² University of Chinese Academy of Sciences, Beijing, China.
³ Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China.
⁴ School of Pharmacy, Fudan University, Shanghai, China.
⁵ The National Center for Drug Screening and CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CAS), Shanghai, China. dhyang@simm.ac.cn.
⁶ University of Chinese Academy of Sciences, Beijing, China. dhyang@simm.ac.cn.
⁷ Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China. bodai1978@126.com.
⁸ The National Center for Drug Screening and CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CAS), Shanghai, China. mwwang@simm.ac.cn.
⁹ University of Chinese Academy of Sciences, Beijing, China. mwwang@simm.ac.cn.
¹⁰ School of Pharmacy, Fudan University, Shanghai, China. mwwang@simm.ac.cn.

^# Contributed equally.

PMID: 34168114
PMCID: PMC8225807
DOI: 10.1038/s41392-021-00583-7

GPR160 is a potential biomarker associated with prostate cancer

Wanjing Guo et al. Signal Transduct Target Ther. 2021.

. 2021 Jun 25;6(1):241.

doi: 10.1038/s41392-021-00583-7.

Authors

Wanjing Guo^#^{1

2}, Junyu Zhang^#³, Yan Zhou¹, Caihong Zhou¹, Yunjie Yang³, Zhaotong Cong⁴, Jibin Dong⁴, Dehua Yang^{5

6}, Bo Dai⁷, Ming-Wei Wang^{8

9

10}

Affiliations

¹ The National Center for Drug Screening and CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CAS), Shanghai, China.
² University of Chinese Academy of Sciences, Beijing, China.
³ Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China.
⁴ School of Pharmacy, Fudan University, Shanghai, China.
⁵ The National Center for Drug Screening and CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CAS), Shanghai, China. dhyang@simm.ac.cn.
⁶ University of Chinese Academy of Sciences, Beijing, China. dhyang@simm.ac.cn.
⁷ Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China. bodai1978@126.com.
⁸ The National Center for Drug Screening and CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CAS), Shanghai, China. mwwang@simm.ac.cn.
⁹ University of Chinese Academy of Sciences, Beijing, China. mwwang@simm.ac.cn.
¹⁰ School of Pharmacy, Fudan University, Shanghai, China. mwwang@simm.ac.cn.

^# Contributed equally.

PMID: 34168114
PMCID: PMC8225807
DOI: 10.1038/s41392-021-00583-7

No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1 — Fig. 1
Higher expression of GPR160 in cancerous human prostate tissues and relationship between GPR160 expression levels and clinical characteristics of enrolled patients. a Images of GPR160 expression detected by RNAscope^® (mRNA, FISH)) and immunohistochemistry (protein, IHC). HE, hematoxylin and eosin, scale bars, 50 μm. b 143 samples containing both normal and cancerous tissues used for mRNA analysis with paired t test. c 167 samples containing cancerous and 143 samples containing normal tissues used for mRNA analysis with unpaired t test. d 112 samples containing both normal and cancerous tissues used for immunohistochemistry analysis with paired t test. e 140 samples containing cancerous and 112 samples containing normal tissues used analysis with unpaired t test. Data presented are means ± SEM of up to three independent reading; ***P < 0.0001. f Gleason scores vs. GPR160 mRNA levels in the prostate cancer tissue. g Disease stage vs. GPR160 mRNA levels in the prostate cancer tissue. h PSA levels in patients with elevated GPR160 mRNA transcription. i Age-related GPR160 protein intensity. j M scores in patients with or without GPR160 protein expression. Data shown are means ± SEM; *P < 0.05 using unpaired t test. k Expression of the epithelial–mesenchymal transition (EMT) hallmarks E-cadherin, N-cadherin, and vimentin as well as GPR160 in blank and GPR160 gene transfected cells. l Quantitative densitometric analysis of k. m Expression of the three EMT hallmarks and GPR160 in blank and GPR160 gene silenced cells. n Quantitative densitometric analysis of m. o Expression of the EMT hallmarks ZO-1, snail, and fibronectin 1 in blank and GPR160 gene silenced cells. p Quantitative densitometric analysis of o. q Expression of the EMT hallmarks ZO-1, snail, and fibronectin 1 in blank and GPR160 gene transfected RWPE-1 cells. r Quantitative densitometric analysis of q. s Expression of the EMT hallmarks ZO-1, snail, and fibronectin 1 in blank and GPR160 gene transfected WPMY-1 cells. t Quantitative densitometric analysis of s. u, Migration of GPR160 gene silenced or transfected cells. v Quantitative densitometric analysis of u. w Invasion of GPR160 gene silenced or transfected cells. x Quantitative densitometric analysis of w. y Wound-healing assay in GPR160 gene silenced or transfected cells. Data presented are means ± SEM obtained from three independent experiments; *P < 0.05, **P < 0.01, and ***P < 0.001 using Student’s t test

See this image and copyright information in PMC

Similar articles

G protein-coupled receptor GPR160 is associated with apoptosis and cell cycle arrest of prostate cancer cells.
Zhou C, Dai X, Chen Y, Shen Y, Lei S, Xiao T, Bartfai T, Ding J, Wang MW. Zhou C, et al. Oncotarget. 2016 Mar 15;7(11):12823-39. doi: 10.18632/oncotarget.7313. Oncotarget. 2016. PMID: 26871479 Free PMC article.
Prostate-Specific G-Protein Coupled Receptor, an Emerging Biomarker Regulating Inflammation and Prostate Cancer Invasion.
Rodriguez M, Siwko S, Liu M. Rodriguez M, et al. Curr Mol Med. 2016;16(6):526-32. doi: 10.2174/1566524016666160607091333. Curr Mol Med. 2016. PMID: 27280498 Review.
Leucine-rich repeat-containing G protein-coupled receptor 4 (Lgr4) is necessary for prostate cancer metastasis via epithelial-mesenchymal transition.
Luo W, Tan P, Rodriguez M, He L, Tan K, Zeng L, Siwko S, Liu M. Luo W, et al. J Biol Chem. 2017 Sep 15;292(37):15525-15537. doi: 10.1074/jbc.M116.771931. Epub 2017 Aug 2. J Biol Chem. 2017. PMID: 28768769 Free PMC article.
A novel human G protein-coupled receptor is over-expressed in prostate cancer.
Parmigiani RB, Magalhães GS, Galante PA, Manzini CV, Camargo AA, Malnic B. Parmigiani RB, et al. Genet Mol Res. 2004 Dec 30;3(4):521-31. Genet Mol Res. 2004. PMID: 15688318
The role of prostate tumor overexpressed 1 in cancer progression.
Cánovas V, Lleonart M, Morote J, Paciucci R. Cánovas V, et al. Oncotarget. 2017 Feb 14;8(7):12451-12471. doi: 10.18632/oncotarget.14104. Oncotarget. 2017. PMID: 28029646 Free PMC article. Review.

See all similar articles

Cited by

Therapeutic and prognostic potential of GPCRs in prostate cancer from multi-omics landscape.
Li S, Chen J, Chen X, Yu J, Guo Y, Li M, Pu X. Li S, et al. Front Pharmacol. 2022 Aug 30;13:997664. doi: 10.3389/fphar.2022.997664. eCollection 2022. Front Pharmacol. 2022. PMID: 36110544 Free PMC article.
Expression quantitative trait loci influence DNA damage-induced apoptosis in cancer.
Bigge J, Koebbe LL, Giel AS, Bornholdt D, Buerfent B, Dasmeh P, Zink AM, Maj C, Schumacher J. Bigge J, et al. BMC Genomics. 2024 Dec 2;25(1):1168. doi: 10.1186/s12864-024-11068-6. BMC Genomics. 2024. PMID: 39623312 Free PMC article.
GPR162 is a beta cell CART receptor.
Lindqvist A, Abels M, Shcherbina L, Ngara M, Kryvokhyzha D, Chriett S, Riva M, Fajul A, Barghouth M, Luan C, Eliasson L, Larsen O, Rosenkilde MM, Zhang E, Renström E, Wierup N. Lindqvist A, et al. iScience. 2023 Nov 10;26(12):108416. doi: 10.1016/j.isci.2023.108416. eCollection 2023 Dec 15. iScience. 2023. PMID: 38077141 Free PMC article.
High expression of GPR160 in prostate cancer is unrelated to CARTp-mediated signaling pathways.
Ye C, Zhou Q, Lin S, Yang W, Cai X, Mai Y, Chen Y, Yang D, Wang MW. Ye C, et al. Acta Pharm Sin B. 2024 Mar;14(3):1467-1471. doi: 10.1016/j.apsb.2023.11.025. Epub 2023 Nov 24. Acta Pharm Sin B. 2024. PMID: 38487007 Free PMC article. No abstract available.

References

1. Ferlay J, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J. Cancer. 2015;136:E359–E386. doi: 10.1002/ijc.29210. - DOI - PubMed
1. Yosten GL, et al. GPR160 de-orphanization reveals critical roles in neuropathic pain in rodents. J. Clin. Invest. 2020;130:2587–2592. doi: 10.1172/JCI133270. - DOI - PMC - PubMed
1. Zhou C, et al. G protein-coupled receptor GPR160 is associated with apoptosis and cell cycle arrest of prostate cancer cells. Oncotarget. 2016;7:12823–12839. doi: 10.18632/oncotarget.7313. - DOI - PMC - PubMed
1. Chaffer CL, San Juan BP, Lim E, Weinberg RA. EMT, cell plasticity and metastasis. Cancer Metastasis Rev. 2016;35:645–654. doi: 10.1007/s10555-016-9648-7. - DOI - PubMed
1. Gopal G, Shirley S, Raja UM, Rajkumar T. Endo-sulfatase Sulf-1 protein expression is down-regulated in gastric cancer. Asian Pac. J. Cancer Prev. 2012;13:641–646. doi: 10.7314/APJCP.2012.13.2.641. - DOI - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information
Molecular Biology Databases
- GlyGen glycoinformatics resource